Dear Molecular Imaging Insider,
SPECT myocardial perfusion imaging has proven value for predicting major adverse cardiovascular events in patients with heart disease. Yet the timing and specific type of these events remains largely a mystery for clinicians.
Can artificial intelligence (AI) help? A team at Cedars-Sinai Medical Center in Los Angeles believes so. The group recently developed a deep-learning model that appears to predict specific event types (such as death or myocardial infarction), as well as offer a time window for when they may occur. You can read about the findings in this edition's Insider Exclusive.
This and other research we've recently covered suggests that the use of AI in nuclear medicine is gaining momentum. For instance, a group in South Korea developed a model for classifying stages of Alzheimer's disease using details from patient F-18 flortaucipir PET images; in another study, researchers suggested an AI model trained on whole-body scintigraphy images could be used to identify patients at risk of cardiac amyloidosis.
At the recent American Roentgen Ray Society (ARRS) annual meeting, a bevy of nuclear medicine research was highlighted. In one session, Dr. Don Yoo of Brown University in Providence, RI, discussed the evolution of prostate-specific membrane antigen (PSMA)-PET/CT -- specifically, how PSMA-PET/CT has emerged as a key approach for diagnosing prostate cancer and monitoring patients receiving lutetium-177 PSMA-617 (Pluvicto) treatment. (While none of the discussion concerned GE's supply issues with the drug, we've been keeping tabs on the latest news.)
That's not all. Here are several other stories we posted from research presented at the ARRS meeting:
- Simultaneous PET/MR enterography can improve the detection of active inflammatory Crohn's disease, according to a group at the University of Wisconsin.
- PET/CT imaging shows that COVID-19 mRNA vaccines cause higher rates of reactive lymph nodes in cancer patients compared with whole-virus vaccines, a group at Yale suggested.
- Dr. Huong Le-Petross of the University of Texas MD Anderson Cancer Center recommended PET/CT as a first-line approach in women with inflammatory breast cancer.
Finally, we covered a study that explored whether sentinel lymph node specimens remain radioactive after lymphoscintigraphies -- and it turns out they're not radioactive enough to warrant special labeling and shipping precautions, according to a team at Mount Sinai Hospital in Toronto, Canada.
Stay tuned for our next issue, where we'll be highlighting research presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) 2023 annual meeting to be held June 24 to 27 in Chicago.
In the meantime, be sure to check back regularly for more news in our Molecular Imaging Community!